Skip to main content
OpenTrials
Completed

NCT Number: NCT03976037

Buccal Versus Vaginal Misoprostol In Combination With Foley Bulb

Combined misoprostol and Foley bulb catheter has been shown to be an effective induction method. However, optimal route of administration for misoprostol has not been established.

Therefore, the purpose of this study is to compare the effectiveness and safety of combination buccal miso-foley to combination vaginal miso-foley for third trimester cervical ripening and induction of labor.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–55 year

Sex eligibility

Female

Study type

Interventional

Phase

Early Phase 1

Primary location

Christiana Care Health Systems

Newark, Delaware, 19713, United States

About this study

This randomized controlled trial of consenting women undergoing induction of labor with combined misoprostol and Foley catheter seeks to efficacy of vaginal versus buccal misoprostol route of administration.

This project will include 216 women presenting at Christiana Care Health System. Women will be included if they are at least 37 weeks gestation, have a singleton pregnancy, have intact membranes and are undergoing an induction of labor using a Foley catheter combined with misoprostol. Following admission, women will be randomized into either vaginal or buccal misoprostol.

Women will be randomized with equal probability to the intervention group using block randomization stratified by party.

Patients will receive 25 micrograms of misoprostol along with the insertion of a16F Foley catheter. Misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. The remainder of labor management will be at the discretion of each woman's obstetric provider.

Prior to discharge from the hospital, baseline demographic and clinical data will be obtained via chart review

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ≥18 years of age
  • full term (≥37 weeks) gestations determined by routine obstetrical guidelines
  • singleton gestation in cephalic presentation
  • Both nulliparous and multiparous women
  • Intact membranes
  • Cervical dilation ≤2cm

Exclusion criteria

  • Any contraindication to a vaginal delivery or to misoprostol
  • fetal demise
  • Multifetal gestation
  • prior uterine surgery, previous cesarean section
  • Tachysystole was defined as at least 6 contractions in 10 minutes for 2 consecutive 10-minute periods
  • women with HIV, and women with medical conditions requiring an assisted second stage
  • Additional exclusion criteria were as follows: category 3 fetal heart rate tracing, hemolysis elevated liver enzymes and low platelets (HELLP) syndrome or eclampsia, growth restriction <10th percentile (based on Hadlock growth curves) with reversal of flow in umbilical artery Doppler studies, and growth restriction <5th percentile with elevated, absent, or reversal of flow in umbilical artery Doppler studies

As described in previous research (Levine LD, Downes KL, Elovitz MA, Parry S, Sammel MD, Srinivas SK. Mechanical and Pharmacologic Methods of Labor Induction: A Randomized Controlled Trial. Obstet Gynecol. 2016;128(6):1357-1364)

Treatment and study plan

Misoprostol

Drug

Women randomized to either vaginal or buccal misoprostol-cervical Foley group will have both misoprostol and a cervical Foley placed. Patients will receive 25 micrograms of vaginal or buccal misoprostol along with the insertion of a16F Foley catheter with stylet. The Foley balloon catheter will be filled with 30cc balloon inserted digitally or by direct visualization with a speculum. The Foley bulb will be placed just above the level of the internal os and inflated with 30cc of sterile water.

vaginal or Buccal misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. If the patient is contracting more than 3 times per 10 minutes after 6 hours, oxytocin protocol is initiated.

Other names: cytotec

Primary outcomes

  1. time to delivery (hours) defined

    Time frame: through study completion, an average of 2 year

    as time from initiation of induction method to delivery time, regardless of mode of delivery.

Secondary outcomes

  1. Rate of Cesarean delivery

    Time frame: through study completion, an average of 2 year

    yes/no

  2. Time to active labor

    Time frame: through study completion, an average of 2 year

    s time from initiation of induction method to dilatation ≥6cm

  3. Maternal length of stay

    Time frame: through study completion, an average of 2 year

    defined as length of time from admission for induction to discharge postpartum, days

  4. Indication for cesarean delivery

    Time frame: through study completion, an average of 2 year

    The reason for induction: NRFHT, arrest of dilation, arrest of descent, failed IOL, other

  5. Rate of 3rd/4th degree perineal laceration

    Time frame: through study completion, an average of 2 year

    yes/no

  6. Rate of Maternal Blood transfusion

    Time frame: through study completion, an average of 2 year

    yes/no

  7. Rate of Endometritis

    Time frame: through study completion, an average of 2 year

    yes/no; fundal tenderness and fever that required treatment with antibiotics

  8. Rate of Wound separation-infection

    Time frame: From time of delivery to time of hospital discharge; up to 6 weeks

    the need for additional wound closure or the need for antibiotics

  9. Rate of Venous thromboembolism

    Time frame: through study completion, an average of 2 year

    yes/no

  10. Rate of Hysterectomy

    Time frame: through study completion, an average of 2 year

    yes/no

  11. Rate of Intensive care unit admission

    Time frame: through study completion, an average of 2 year

    yes/no

  12. Rate of Maternal Death

    Time frame: through study completion, an average of 2 year

    yes/no

  13. Rate of Chorioamnionitis

    Time frame: through study completion, an average of 2 year

    the presence of maternal fever ≥100·4°f in the presence of maternal or fetal tachycardia or fundal tenderness

  14. Rate of terbutaline use

    Time frame: through study completion, an average of 2 year

    yes/no

  15. Rate of Intrauterine pressure catheter use

    Time frame: through study completion, an average of 2 year

    yes/no

  16. Rate of Amnioinfusion

    Time frame: through study completion, an average of 2 year

    yes/no

  17. Rate of Analgesia use

    Time frame: through study completion, an average of 2 year

    yes/no

  18. Rate of Severe respiratory distress syndrome

    Time frame: From time of delivery to hospital discharge; up to 6 weeks

    defined as intubation and mechanical ventilation for a minimum of 12 hours

  19. Rate of Culture proven-presumed neonatal sepsis

    Time frame: From time of delivery to hospital discharge; up to 6 weeks

    yes/no

  20. Rate of Neonatal blood transfusion

    Time frame: From time of delivery to hospital discharge; up to 6 weeks

    yes/no

  21. Rate of Hypoxic ischemic encephalopathy

    Time frame: From time of delivery to hospital discharge; up to 6 weeks

    yes/no

  22. Rate of Intraventricular hemorrhage grade 3 or 4

    Time frame: From time of delivery to hospital discharge; up to 6 weeks

    yes/no

  23. Rate of Necrotizing enterocolitis

    Time frame: From time of delivery to hospital discharge; up to 6 weeks

    yes/no

  24. Rate of head cooling.

    Time frame: From time of delivery to hospital discharge; up to 6 weeks

    yes/no

  25. Rate of NICU admission

    Time frame: From time of delivery to hospital discharge; up to 6 weeks

    yes/no

Sponsors and collaborators

Lead sponsor

Christiana Care Health Services

Other

Registry information

Official study title

Buccal Versus Vaginal Misoprostol In Combination With Foley Bulb for Labor Induction at Term: a Randomized Controlled Trial

Acronym: BEGIN

Important dates

Study start
2019
Primary completion
2020
Study completion
2021
First posted
Jun 5, 2019
Registry last updated
Feb 26, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.